[ad_1]
The Russian coronavirus vaccine, called Sputnik-V, produced antibodies in all volunteers who participated in the first two phases of clinical trials, according to preliminary results published in the internationally acclaimed medical journal Lancet, which are a response to criticism. from Moscow. for the vaccine.
The results of the two phases of the clinical trials, which took place in the period June-July and in which 76 volunteers participated, showed that 100% of the participants in these trials developed antibodies against the new coronavirus without serious side effects, writes the Lancet magazine.
Russia, according to the Agency of Athens and Macedonia, approved the vaccine in August after completing the first two phases of clinical trials and was the first country in the world to approve a vaccine before the completion of the third phase of clinical trials. participation of thousands of people.
“In the first two phases of 42 days each, in which 38 healthy volunteers participated, there were no serious side effects among the participants and they confirmed that the candidate vaccine produces antibodies. “writes The Lancet.
Large-scale long-term clinical trials, including placebo comparisons and follow-up, are needed to confirm the long-term safety and efficacy of the vaccine against Covid-19 infection, according to the article.
The first Russian vaccine against the new coronavirus was given the symbolic name Sputnik-V, since Sputnik was the world’s first satellite sent into space by the Soviet Union.
Several Western experts had expressed doubts about the Russian vaccine because it was approved and used before all phases of the internationally defined clinical trials were completed.
However, the results, first published in an internationally acclaimed journal, with the final third phase of clinical trials involving 40,000 people starting last week, have refuted claims by Moscow critics abroad that a high Official Russian civil servant.
“This article answers all the questions that the West has been diligently asking for the past three weeks, openly and with the clear aim of tarnishing the Russian vaccine,” said Kirill Dmitriev, director of the Russian Direct Investment Fund (RDIF), a fund independent state. that has funded the development of the vaccine. “All the packages have been tested,” he told Reuters, adding: “Now … we will start asking questions about some vaccines in the West.”
Dmitriev said that some 3,000 people had already started to participate in the third phase of clinical trials of the Sputnik-V vaccine, which began last week, and that the first results are expected in October or November of this year.
According to Alexander Ginzburg, director of the Russian Gamaley Center for Epidemiology, where the first clinical trials were conducted, doctors will closely monitor participants in the third phase of clinical trials. They will not be hospitalized, but they will undergo all the necessary tests before the start of clinical trials, during them and once they are finished. Volunteers will be able to report any side effects directly to physicians if they occur.
Commenting on the results of the first two phases of clinical trials of the Russian Sputnik-V vaccine, Dr. Naor Bar Zeef of the International Center for Access to Vaccines and a professor at the Bloomberg School of Public Health at Johns Hopkins said : ». Bar Zeef, who was not involved in the study, said that “the clinical efficacy of any vaccine against Covid-19 has not yet been demonstrated.”
[ad_2]
